H.C. Wainwright says the bar is set for oral GLP-1s following this morning’s type 2 diabetes data from Eli Lilly (LLY). The ...

Insights from analysts' 12-month price targets are revealed, presenting an average target of $17.08, a high estimate of ...

Portfolio of miniature, once or twice-yearly GLP-1 implants in development for chronic weight management and type 2 diabetes ...

H.C. Wainwright raised the firm’s price target on Oculis (OCS) to $32 from $29 and keeps a Buy rating on the shares. The firm says the ...

HC Wainwright analyst R. Selvaraju now anticipates that the biotechnology company will earn ($0.13) per share for the quarter, up from their previous forecast of ($0.15).

H.C. Wainwright analyst Amit Dayal lowered the firm’s price target on ClearSign (CLIR) to $2 from $6 and keeps a Buy rating on the shares. The ...

Evolus, Inc. (NASDAQ:EOLS – Free Report) – Investment analysts at HC Wainwright dropped their FY2025 earnings per share estimates for Evolus in a report released on Thursday, April 10th.

We recently published a list of the 11 Most Promising Penny Stocks According to Analysts. In this article, we are going to ...

Analysts have recently evaluated Verve Therapeutics and provided 12-month price targets. The average target is $17.5, ...

We recently published a list of the 10 Best Rising Penny Stocks to Buy According to Analysts. In this article, we are going ...

The gross proceeds from the, before deducting the placement agent's fees and other offering expenses payable by the Company, ...